Survival Score to Characterize Prognosis in Inoperable Stage III NSCLC After Chemoradiotherapy

Overview

Journal Transl Lung Cancer Res

Date 2019 Nov 19

PMID 31737496

Citations 10

Authors

Julian Taugner

Lukas Kasmann

Chukwuka Eze

Maurice Dantes

Olarn Roengvoraphoj

Kathrin Gennen

Monika Karin

Oleg Petruknov

Amanda Tufman

Claus Belka

Farkhad Manapov

Affiliations

Soon will be listed here.

Abstract

Background: Stage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease regarding principal patient- and tumor characteristics. A simple score may aid in personalizing multimodal therapy.

Methods: The data of 99 consecutive patients with performance status ECOG 0-1 treated until the end of 2016 with multimodal approach for inoperable NSCLC (UICC 7 edition stage IIIA/B) were evaluated. Patient- and tumor-related factors were examined for their impact on overall survival. Factors showing a negative association with prognosis were then included in the score. Three subgroups with low, intermediate and high-risk score were defined. The results were then validated in the prospective cohort, which includes 45 patients.

Results: Most Patients were treated with concurrent (78%) or sequential (11%) chemoradiotherapy. 53% received induction chemotherapy. Median survival for the entire cohort was 20.8 (range: 15.3-26.3) months. Age (P=0.020), gender (P=0.007), pack years (P=0.015), tumor-associated atelectasis (P=0.004) and histology (P=0.004) had a significant impact on overall survival and were scored with one point each. Twelve, 59 and 28 patients were defined to have a low (0-1 points), intermediate (2-3 points) and high-risk (4-5 points) score. Median survival, 1-, 2- and 3-year survival rates were not reached, 100%, 83% and 67% in the low, 22.9 months, 80%, 47% and 24% intermediate and 13.7 months, 57%, 25% and 18% high-risk patients, respectively (P<0.001). Median survival was not reached in prospective cohort; analysis has revealed a trend for the 1-year survival rates with 100% for the low, 93% intermediate and 69% high-risk patients (P=0.100).

Conclusions: The score demonstrated remarkable survival differences in inoperable stage III NSCLC patients with good performance status receiving multimodal therapy.

Citing Articles

A visualization analysis of immune-related adverse reactions in pulmonary carcinoma.

Gong Y, Kang J, Wang M, Firdaus Mohd Hayati M, Wah Goh L, Bin Syed Abdul Rahim S Hum Vaccin Immunother. 2024; 20(1):2429237.

PMID: 39588915 PMC: 11601054. DOI: 10.1080/21645515.2024.2429237.

First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.

Hofstetter K, Taugner J, Kasmann L, Mansoorian S, Florsch B, Eze C Strahlenther Onkol. 2023; 200(7):614-623.

PMID: 37975883 PMC: 11186867. DOI: 10.1007/s00066-023-02175-6.

Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by....

Kasmann L, Taugner J, Eze C, Nieto A, Pelikan C, Florsch B Transl Lung Cancer Res. 2022; 11(7):1503-1509.

PMID: 35958344 PMC: 9359949. DOI: 10.21037/tlcr-21-1010.

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.

Florsch B, Taugner J, Kasmann L, Kenndoff S, Guggenberger J, Tufman A J Cancer Res Clin Oncol. 2022; 149(7):3267-3276.

PMID: 35915184 PMC: 10314870. DOI: 10.1007/s00432-022-04174-z.

Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data.

Nieva J, Reckamp K, Potter D, Taylor A, Sun P Drugs Real World Outcomes. 2022; 9(3):333-345.

PMID: 35661118 PMC: 9392819. DOI: 10.1007/s40801-022-00302-w.

References

Hallqvist A, Bergstrom S, Bjorkestrand H, Svard A, Ekman S, Lundin E . Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial. Lung Cancer. 2018; 122:180-186. DOI: 10.1016/j.lungcan.2018.06.020. View

Alexander M, Wolfe R, Ball D, Conron M, Stirling R, Solomon B . Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. Br J Cancer. 2017; 117(5):744-751. PMC: 5572183. DOI: 10.1038/bjc.2017.232. View

Mahar A, Compton C, McShane L, Halabi S, Asamura H, Rami-Porta R . Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools. J Thorac Oncol. 2015; 10(11):1576-89. PMC: 4636439. DOI: 10.1097/JTO.0000000000000652. View

Pollom E, Qian Y, Durkee B, von Eyben R, Maxim P, Shultz D . Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016; 17(6):588-594. DOI: 10.1016/j.cllc.2016.05.024. View

Forrest L, McMillan D, McArdle C, Angerson W, Dunlop D . Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89(6):1028-30. PMC: 2376960. DOI: 10.1038/sj.bjc.6601242. View

Dieleman E, Uitterhoeve A, van Hoek M, van Os R, Wiersma J, Koolen M . Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018; 102(3):543-551. DOI: 10.1016/j.ijrobp.2018.07.188. View

Flentje M, Huber R, Engel-Riedel W, Andreas S, Kollmeier J, Staar S . GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016; 192(4):216-22. DOI: 10.1007/s00066-016-0941-8. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Dutkowska A, Antczak A . Comorbidities in lung cancer. Pneumonol Alergol Pol. 2016; 84(3):186-92. DOI: 10.5603/PiAP.2016.0022. View

10.

Eberhardt W, Pottgen C, Gauler T, Friedel G, Veit S, Heinrich V . Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015; 33(35):4194-201. DOI: 10.1200/JCO.2015.62.6812. View

11.

Maguire J, Khan I, McMenemin R, ORourke N, McNee S, Kelly V . SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer. 2014; 50(17):2939-49. DOI: 10.1016/j.ejca.2014.07.009. View

12.

Forde P, Chaft J, Smith K, Anagnostou V, Cottrell T, Hellmann M . Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378(21):1976-1986. PMC: 6223617. DOI: 10.1056/NEJMoa1716078. View

13.

Senan S, Brade A, Wang L, Vansteenkiste J, Dakhil S, Biesma B . PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(9):953-62. DOI: 10.1200/JCO.2015.64.8824. View

14.

Brundage M, Davies D, Mackillop W . Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002; 122(3):1037-57. DOI: 10.1378/chest.122.3.1037. View

15.

Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J . The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999; 45(5):1143-9. DOI: 10.1016/s0360-3016(99)00325-9. View

16.

Gagnon B, Agulnik J, Gioulbasanis I, Kasymjanova G, Morris D, Macdonald N . Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers. Br J Cancer. 2013; 109(8):2066-71. PMC: 3798950. DOI: 10.1038/bjc.2013.515. View

17.

Iqbal M, Vashisht G, McMenemin R, Atherton P, McDonald F, Simmons T . Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review. Clin Oncol (R Coll Radiol). 2018; 31(2):e1-e10. DOI: 10.1016/j.clon.2018.10.006. View

18.

Manapov F, Roengvoraphoj O, Li M, Eze C . Moderate hypofractionated image-guided thoracic radiotherapy for locally advanced node-positive non-small cell lung cancer patients with very limited lung function: a case report. Radiat Oncol J. 2017; 35(2):180-184. PMC: 5518457. DOI: 10.3857/roj.2017.00129. View

19.

Rades D, Kasmann L, Schild S, Janssen S . A Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer. Clin Lung Cancer. 2016; 17(6):558-562. DOI: 10.1016/j.cllc.2016.05.010. View

20.

Swanick C, Lin S, Sutton J, Naik N, Allen P, Levy L . Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2014; 16(2):156-63. DOI: 10.1016/j.cllc.2014.10.005. View